Biodesix, Inc. filings document the public reporting of a Nasdaq-listed diagnostics company with common stock trading under BDSX. The company’s 8-K reports disclose operating and financial results for its Diagnostic Testing and Development Services activities, including revenue trends, gross margin, guidance, and related press-release exhibits.
Proxy materials cover annual meeting proposals, board and governance matters, and stockholder voting. Other material-event filings document capital-structure and security-holder matters, including the completed one-for-twenty reverse stock split, common stock listing details, Nasdaq minimum bid price compliance, and amendments to the company’s charter.
Biodesix, Inc. insider Chris Vazquez, the Chief Accounting Officer, reported routine equity transactions involving restricted stock units (RSUs) and related tax sales. On January 15, 2026, 219 RSUs vested and were converted into an equal number of shares of Biodesix common stock at an exercise price of $0, consistent with each RSU representing one share. On January 16, 2026, 83 of these common shares were automatically sold at a weighted average price of $8.1493 per share to cover taxes due upon vesting, with prices ranging from $8.10 to $8.28. Following these transactions, Vazquez directly held 1,072 shares of common stock and 436 RSUs, which vest in four equal annual installments from January 15, 2024. The reported share counts have been adjusted for a one-for-twenty reverse stock split effective September 15, 2025.
Biodesix Inc's Chief Development Officer, Gary Pestano, reported routine equity compensation activity. On January 15, 2026, 805 restricted stock units converted into 805 shares of Biodesix common stock at an exercise price of $0 per share, reflecting previously granted RSUs that each represent one share. The RSU figures and related share amounts have been adjusted for a one-for-twenty reverse stock split effective September 15, 2025.
On January 16, 2026, 298 shares of common stock were sold at a weighted average price of $8.1493 per share, with the shares automatically sold to cover taxes due upon RSU vesting. After these transactions, Pestano beneficially owned 8,446 shares of common stock and 1,609 RSUs, which vest in four equal annual installments starting January 15, 2024, generally contingent on continued service.
Biodesix Inc. Chief Commercial Officer Kieran O'Kane reported routine equity compensation activity. On January 15, 2026, 805 restricted stock units (RSUs) were converted into 805 shares of Common Stock at an exercise price of $0, reflecting prior awards adjusted for a one-for-twenty reverse stock split effective September 15, 2025. These RSUs are part of a grant that vests in four equal annual installments starting January 15, 2024, generally conditioned on continued service.
On January 16, 2026, 298 shares of Common Stock were sold at a weighted average price of $8.1493 per share, with prices ranging from $8.10 to $8.28, to cover taxes due upon RSU vesting. After these transactions, O'Kane directly held 7,869 shares of Common Stock and 1,609 RSUs.
Biodesix Inc. President & CEO Scott Hutton reported routine equity award activity and a small share sale. On January 15, 2026, 2,633 restricted stock units (RSUs) vested and were converted into 2,633 shares of Biodesix common stock at an exercise price of $0, reflecting a stock-based compensation award. The RSU and share counts have been adjusted for a one-for-twenty reverse stock split effective September 15, 2025.
On January 16, 2026, 970 shares of common stock were sold at a weighted-average price of $8.1493 per share to automatically cover taxes due upon the RSU vesting. After these transactions, Hutton directly held 38,974 shares of common stock and 5,265 RSUs, which continue to vest in four equal annual installments starting January 15, 2024.
Biodesix, Inc. (BDSX) CFO, Secretary & Treasurer Robin Harper Cowie reported RSU vesting and related tax-share sales. On January 15, 2026, 805 restricted stock units were converted into the same number of Biodesix common shares at an exercise price of $0, increasing her direct common stock holdings to 13,952 shares and RSU holdings to 1,609 units after the transaction.
On January 16, 2026, she sold 298 shares of common stock at a weighted average price of $8.1493 per share. According to the disclosure, these shares were sold automatically by the issuer's broker to cover taxes due upon RSU vesting. Following the sale, she directly owned 13,654 shares of common stock. The filing notes that all share and unit numbers reflect a one-for-twenty reverse stock split effective September 15, 2025, and that the RSUs vest in four equal annual installments starting January 15, 2024.
Soleus Capital Master Fund, L.P. and related entities have filed a Schedule 13G reporting a significant passive stake in Biodesix, Inc. common stock. They report beneficial ownership of 500,000 shares of Biodesix common stock, representing 6.3% of the class, based on 7,955,685 shares outstanding as of October 28, 2025. The shares are held directly by Soleus Capital Master Fund, L.P., with Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC and Guy Levy reported as associated entities and individual. These parties disclaim beneficial ownership of the shares beyond what is required for Section 13(d) reporting. The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Biodesix.
Biodesix, Inc. filed an amended current report to change how its recent earnings press release is treated under securities law. The company previously issued a press release with certain preliminary and unaudited financial results for the fourth quarter and year ended December 31, 2025. Through this amendment, Biodesix is recharacterizing that press release, which is attached as Exhibit 99.1, so that it is considered "filed" rather than "furnished" under the Exchange Act. The company states that no other changes have been made beyond this filing status update.
Biodesix director Jean M. Franchi reported new equity awards dated January 2, 2026. She received 8,164 restricted stock units (RSUs), each representing one share of Biodesix common stock. These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally conditioned on her continued service, and a portion is structured as deferred RSUs that will be settled in shares after her separation from the company. She was also granted 6,354 stock options with an exercise price of $6.46 per share, vesting in four substantially equal installments on the same 2026 dates, also tied to continued service.
Biodesix director Matthew Strobeck reported new equity awards. On January 2, 2026, he received 6,804 restricted stock units (RSUs), each representing one share of Biodesix common stock. These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026 and some are deferred so the underlying shares will be delivered after his separation from service.
On the same date, he was also granted 6,354 stock options with an exercise price of $6.46 per share, vesting in four substantially equal installments on the same 2026 dates and expiring on January 1, 2036. All awards are generally subject to his continued service as a director.
Biodesix Inc. director Hany Massarany reported new equity awards. On January 2, 2026, he received 7,484 restricted stock units (RSUs), each representing one share of Biodesix common stock. These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally conditioned on continued service.
Some of the RSUs are deferred, with the underlying shares to be issued after his separation from service. Massarany was also granted stock options for 6,354 shares at an exercise price of $6.46 per share, vesting in four substantially equal installments on the same 2026 dates, also generally subject to continued service.